201 related articles for article (PubMed ID: 35657979)
1. Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study.
Lee KW; Van Cutsem E; Bang YJ; Fuchs CS; Kudaba I; Garrido M; Chung HC; Lee J; Castro HR; Chao J; Wainberg ZA; Cao ZA; Aurora-Garg D; Kobie J; Cristescu R; Bhagia P; Shah S; Tabernero J; Shitara K; Wyrwicz L
Clin Cancer Res; 2022 Aug; 28(16):3489-3498. PubMed ID: 35657979
[TBL] [Abstract][Full Text] [Related]
2. Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma.
Shitara K; Özgüroğlu M; Bang YJ; Di Bartolomeo M; Mandalà M; Ryu MH; Caglevic C; Chung HC; Muro K; Van Cutsem E; Kobie J; Cristescu R; Aurora-Garg D; Lu J; Shih CS; Adelberg D; Cao ZA; Fuchs CS
Ann Oncol; 2021 Sep; 32(9):1127-1136. PubMed ID: 34082019
[TBL] [Abstract][Full Text] [Related]
3. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.
Cristescu R; Aurora-Garg D; Albright A; Xu L; Liu XQ; Loboda A; Lang L; Jin F; Rubin EH; Snyder A; Lunceford J
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101941
[TBL] [Abstract][Full Text] [Related]
4. Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.
Bellmunt J; de Wit R; Fradet Y; Climent MA; Petrylak DP; Lee JL; Fong L; Necchi A; Sternberg CN; O'Donnell PH; Powles T; Plimack ER; Bajorin DF; Balar AV; Castellano D; Choueiri TK; Culine S; Gerritsen W; Gurney H; Quinn DI; Vuky J; Vogelzang NJ; Cristescu R; Lunceford J; Saadatpour A; Loboda A; Ma J; Rajasagi M; Godwin JL; Homet Moreno B; Grivas P
Clin Cancer Res; 2022 May; 28(10):2050-2060. PubMed ID: 35247908
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials.
Chao J; Fuchs CS; Shitara K; Tabernero J; Muro K; Van Cutsem E; Bang YJ; De Vita F; Landers G; Yen CJ; Chau I; Elme A; Lee J; Özgüroglu M; Catenacci D; Yoon HH; Chen E; Adelberg D; Shih CS; Shah S; Bhagia P; Wainberg ZA
JAMA Oncol; 2021 Jun; 7(6):895-902. PubMed ID: 33792646
[TBL] [Abstract][Full Text] [Related]
6. Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.
Ledermann JA; Shapira-Frommer R; Santin AD; Lisyanskaya AS; Pignata S; Vergote I; Raspagliesi F; Sonke GS; Birrer M; Provencher DM; Sehouli J; Colombo N; González-Martín A; Oaknin A; Ottevanger PB; Rudaitis V; Kobie J; Nebozhyn M; Edmondson M; Sun Y; Cristescu R; Jelinic P; Keefe SM; Matulonis UA
Gynecol Oncol; 2023 Nov; 178():119-129. PubMed ID: 37862791
[TBL] [Abstract][Full Text] [Related]
7. Clinical evidence for efficacy of pembrolizumab in MSI-H and TMB-H advanced solid tumor: results from three cancer centers in China.
Yan H; Song L; Li Y; Xu Q; Guo W; Lin S; Jiang W; Wang Z; Deng L; Huang Z; Qin H; Zhang X; Tong F; Zhang R; Liu Z; Zhang L; Yu J; Dong X; Gong Q; Deng J; Chen X; Wang J; Zhang G; Yang N; Zhang Y; Zeng L
Cancer Immunol Immunother; 2024 Mar; 73(4):74. PubMed ID: 38451314
[TBL] [Abstract][Full Text] [Related]
8. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers.
Palmeri M; Mehnert J; Silk AW; Jabbour SK; Ganesan S; Popli P; Riedlinger G; Stephenson R; de Meritens AB; Leiser A; Mayer T; Chan N; Spencer K; Girda E; Malhotra J; Chan T; Subbiah V; Groisberg R
ESMO Open; 2022 Feb; 7(1):100336. PubMed ID: 34953399
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer.
Muro K; Shitara K; Yamaguchi K; Yoshikawa T; Satake H; Hara H; Sugimoto N; Machida N; Goto M; Kawakami H; Amagai K; Omuro Y; Esaki T; Hironaka S; Nishina T; Komatsu Y; Matsubara H; Shiratori S; Han S; Satoh T; Ohtsu A
J Gastrointest Cancer; 2023 Sep; 54(3):951-961. PubMed ID: 37037952
[TBL] [Abstract][Full Text] [Related]
10. Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial.
Shitara K; Di Bartolomeo M; Mandala M; Ryu MH; Caglevic C; Olesinski T; Chung HC; Muro K; Goekkurt E; McDermott RS; Mansoor W; Wainberg ZA; Shih CS; Kobie J; Nebozhyn M; Cristescu R; Cao ZA; Loboda A; Özgüroğlu M
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37399357
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10.
Wainberg ZA; Fuchs CS; Tabernero J; Shitara K; Muro K; Van Cutsem E; Bang YJ; Chung HC; Yamaguchi K; Varga E; Chen JS; Hochhauser D; Thuss-Patience P; Al-Batran SE; Garrido M; Kher U; Shih CS; Shah S; Bhagia P; Chao J
Clin Cancer Res; 2021 Apr; 27(7):1923-1931. PubMed ID: 33446564
[TBL] [Abstract][Full Text] [Related]
12. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Marabelle A; Fakih M; Lopez J; Shah M; Shapira-Frommer R; Nakagawa K; Chung HC; Kindler HL; Lopez-Martin JA; Miller WH; Italiano A; Kao S; Piha-Paul SA; Delord JP; McWilliams RR; Fabrizio DA; Aurora-Garg D; Xu L; Jin F; Norwood K; Bang YJ
Lancet Oncol; 2020 Oct; 21(10):1353-1365. PubMed ID: 32919526
[TBL] [Abstract][Full Text] [Related]
13. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.
Schrock AB; Ouyang C; Sandhu J; Sokol E; Jin D; Ross JS; Miller VA; Lim D; Amanam I; Chao J; Catenacci D; Cho M; Braiteh F; Klempner SJ; Ali SM; Fakih M
Ann Oncol; 2019 Jul; 30(7):1096-1103. PubMed ID: 31038663
[TBL] [Abstract][Full Text] [Related]
14. Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study.
Friedman CF; Hainsworth JD; Kurzrock R; Spigel DR; Burris HA; Sweeney CJ; Meric-Bernstam F; Wang Y; Levy J; Grindheim J; Shames DS; Schulze K; Patel A; Swanton C
Cancer Discov; 2022 Mar; 12(3):654-669. PubMed ID: 34876409
[TBL] [Abstract][Full Text] [Related]
15. Universal cutoff for tumor mutational burden in predicting the efficacy of anti-PD-(L)1 therapy for advanced cancers.
Mo SF; Cai ZZ; Kuai WH; Li X; Chen YT
Front Cell Dev Biol; 2023; 11():1209243. PubMed ID: 37305681
[No Abstract] [Full Text] [Related]
16. Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.
Gutierrez M; Lam WS; Hellmann MD; Gubens MA; Aggarwal C; Tan DSW; Felip E; Chiu JWY; Lee JS; Yang JC; Garon EB; Finocchiaro G; Ahn MJ; Luft A; Landers GA; Basso A; Ma H; Kobie J; Palcza J; Cristescu R; Fong L; Snyder A; Yuan J; Herbst RS
Nat Med; 2023 Jul; 29(7):1718-1727. PubMed ID: 37429923
[TBL] [Abstract][Full Text] [Related]
17. Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis.
Loi S; Salgado R; Schmid P; Cortes J; Cescon DW; Winer EP; Toppmeyer DL; Rugo HS; De Laurentiis M; Nanda R; Iwata H; Awada A; Tan AR; Sun Y; Karantza V; Wang A; Huang L; Saadatpour A; Cristescu R; Yearley J; Lunceford J; Jelinic P; Adams S
JCO Precis Oncol; 2023 Apr; 7():e2200317. PubMed ID: 37099733
[TBL] [Abstract][Full Text] [Related]
18. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
Ott PA; Bang YJ; Piha-Paul SA; Razak ARA; Bennouna J; Soria JC; Rugo HS; Cohen RB; O'Neil BH; Mehnert JM; Lopez J; Doi T; van Brummelen EMJ; Cristescu R; Yang P; Emancipator K; Stein K; Ayers M; Joe AK; Lunceford JK
J Clin Oncol; 2019 Feb; 37(4):318-327. PubMed ID: 30557521
[TBL] [Abstract][Full Text] [Related]
19. A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.
Bellone S; Roque DM; Siegel ER; Buza N; Hui P; Bonazzoli E; Guglielmi A; Zammataro L; Nagarkatti N; Zaidi S; Lee J; Silasi DA; Huang GS; Andikyan V; Damast S; Clark M; Azodi M; Schwartz PE; Tymon-Rosario JR; Harold JA; Mauricio D; Zeybek B; Menderes G; Altwerger G; Ratner E; Alexandrov LB; Iwasaki A; Kong Y; Song E; Dong W; Elvin JA; Choi J; Santin AD
Cancer; 2022 Mar; 128(6):1206-1218. PubMed ID: 34875107
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
